Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience
G Salles, M Barrett, R Foà, J Maurer, S O'Brien… - Advances in …, 2017 - Springer
Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …
Past, present, and future of rituximab—the world's first oncology monoclonal antibody therapy
TM Pierpont, CB Limper, KL Richards - Frontiers in oncology, 2018 - frontiersin.org
Rituximab is a chimeric mouse/human monoclonal antibody (mAb) therapy with binding
specificity to CD20. It was the first therapeutic antibody approved for oncology patients and …
specificity to CD20. It was the first therapeutic antibody approved for oncology patients and …
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial
Axicabtagene ciloleucel (axi-cel) demonstrated superior efficacy compared to standard of
care as second-line therapy in patients with high-risk relapsed/refractory (R/R) large B cell …
care as second-line therapy in patients with high-risk relapsed/refractory (R/R) large B cell …
Chimeric antigen receptor T cells in refractory B-cell lymphomas
Background Patients with diffuse large B-cell lymphoma or follicular lymphoma that is
refractory to or that relapses after immunochemotherapy and transplantation have a poor …
refractory to or that relapses after immunochemotherapy and transplantation have a poor …
Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance …
PURPOSE Alliance/CALGB 50303 (NCT00118209), an intergroup, phase III study,
compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide …
compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide …
International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI
Great heterogeneity in survival exists for patients newly diagnosed with diffuse large B-cell
lymphoma (DLBCL). Three scoring systems incorporating simple clinical parameters (age …
lymphoma (DLBCL). Three scoring systems incorporating simple clinical parameters (age …
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis …
V Poeschel, G Held, M Ziepert, M Witzens-Harig… - The Lancet, 2019 - thelancet.com
Background Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin,
vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin …
vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin …
CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP
N Schmitz, S Zeynalova, M Nickelsen… - Journal of Clinical …, 2016 - ascopubs.org
Purpose To develop and validate a risk score for relapse in the CNS in patients with diffuse
large B-cell lymphoma (DLBCL). Patients and Methods A total of 2,164 patients (18 to 80 …
large B-cell lymphoma (DLBCL). Patients and Methods A total of 2,164 patients (18 to 80 …
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity
LH Sehn, RD Gascoyne - Blood, The Journal of the American …, 2015 - ashpublications.org
Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured
with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R …
with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R …
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
H Tilly, MG Da Silva, U Vitolo, A Jack… - Annals of …, 2015 - annalsofoncology.org
Diffuse large B-cell lymphoma (DLBCL) constitutes 30%–58% of non-Hodgkin's lymphoma
series. The crude incidence in Europe is 3.8/100 000/year [1]. The incidence increases with …
series. The crude incidence in Europe is 3.8/100 000/year [1]. The incidence increases with …